NeuMoDx launches 4 new CE-IVD tests

2019 06 26 20 22 6835 Hepatitis Virus 400

NeuMoDx Molecular's IVD assays for four diseases -- hepatitis B, hepatitis C, cytomegalovirus, and Epstein-Barr virus -- received the CE Mark in June and have been launched in the European Union and in other countries that recognize this clearance standard, according to the company.

The assays work with the company's NeuMoDx 96 and NeuMoDx 288 molecular systems.

The company touts high-throughput sample processing and fast turnaround for testing with its NeuMoDx platform, with the first result available in about an hour. In addition to these four tests, the company also markets CE Marked assays for group B Streptococcus and for Chlamydia trachomatis and Neisseria gonorrhoeae.

Page 1 of 1